IRODALOM
1 Molinié F, Gower-Rousseau C, Yzet T, et al. Opposite evolution in incidence of Crohn’s disease and ulcerative colitis
in Northern France (1988-1999). Gut 2004;53:843-848.
2 Card T, Logan RFA, Rodrigues LC, Wheeler JG. Antibioticum use and the developement of Crohn’s disease. Gut
2004;53:246-250.
3 Manguso F, Sanges M, Staiano T. Cigarette smoking and appendectomy are risk factors for extraintestinal
manifestations in ulcerative colitis. Am J Gastroenterol 2004,99:328-334.
4 Masala G, Bagnoli S, Ceroti M et al. Divergent patterns of total and cancer mortality in ulcerative colitis and Crohn’s
disease patients: the Florence IBD study 1978-2001. Gut 2004;53:1309-1313.
5 Franchimont D, Vermeire S, Housni HEI, et al. Deficient hos-bacteria interactions in inflammatory bowel disease?
Toll-like receptor (TLR)-4, Asp299gly polymorphism is associated with Crohn’s disease and ulcerative colitis. Gut
2004;53:987-992.
6 Kugathasan S, Collins N, Maresso K, et al. CARD15 gene mutations and risk for early surgery in pediatric-onset
Crohn’s disease. Clin Gastroenterol Hepatol 2004;2:1003-1009.
7 Ott SJ, Musfeldt M, Wenderoth DF, et al. Reduction in diversity of colonic mucosa associated bacterial microflora in
patients with active inflammatory bowel disease, Gut 2004;53: 685-693.
8 Martin HM, Campbell BJ, Hart CA, et al. Enhanced Escherichia coli adherence and invasion in Crohn’s disease and
colon cancer. Gastroenterology 2004;127:80-93.
9 Naser SA, Ghobrial G, Rornero C, Valentine JF. Culture of Mycobacterium avium subspecies paratuberculosis from
the blood of patients with Crohn’s disease. Lancet 2004;364:1038-1044.
10 Aisenberg J, Legfnani PE, Nilubol N, ..D. Sachar. Are pANCA, ASA, or cytokine gene polymorphisms associated
with pouchitis? Long-term follow-up in 102 ulcerative colitis patients. Am J Gastroenterol 2004;99:432-441.
11
*Cosnes J, Nion-Larmurier I, Afchain P, et al. Gender differences in the response of colitis to smoking. Clin
Gastroenterol Hepatol 2004;41-48.
12 Florin THJ, Pandeya N, Radford-Smith GI. Epidemiology of appendicectomy in primary sclerosing cholangitis and
ulcerative colitis: its influence on the clinical behaviour of the diseases. Gut 2004;53:973-979.
13 Miehsler W, Reinisch W, Valic E, et al. Is inflammatory bowel disease an independent and disease specific risk factor
for thromboembolism? Gut 2004;53:542-548.
14 Solem CA, Loftus EV, Tremaine WJ, Sandborne WJ. Venous thromboembolism in inflammatory bowel disease. Am J
Gastroenterol 2004;97-101.
15 Munk EM, Pedersen L, Floyd A, et al. Inflammatory bowel diseases, 5-aminosalicylic acid and sulfasalazine
treatment and risk of acute pancreatitis: a population-based case-control study. Am J Gastroenterol 2004;99:884-888.
16 Lewis JD, Aberra FN, Lichtenstein GR, et al. Seasonal variation in flares of inflammatory bowel disease.
Gastroenterology 2004;126:665-673.
17 *Jowett SL, Seal CJ, Pearce MS, et al. Influence of dietary factors on the clinical course of ulcerative colitis: a
prospective cohort study. Gut 2004;53:1479-1484.
18 *Tilg H, Kaser A. Diet and relapsing ulcerative colitis: take of the meat? Gut 2004;53:1399-1401.
19 Forcione DG, Rosen MJ, Kisiel JB, Sands BE. Anti-Saccharomyces cerevisiae antibody (ASCA) positivity is
associated with increased risk for early surgery In Crohn’s disease. Gut 2004;53:1117-1122.
20 Winther KV, Jess T, Langholz E, et al. Long-therm risk on cancer in ulcerative colitis: a population-based cohort study
from Copenhagen county. Clin Gastroentero Hepatol 2004;2:1088-1095.
21 Lobel EZ, Korelitz BI, Xuereb MA, Panagopoulos G. A search for the optimal duration of treatment with 6-
mercaptopurine for ulcerative colitis. Am J Gastroemterol 2004;99:462-465.
22 Hanauer SB, Strömberg U. Oral Pentasa in the treatment of active Crohn’s disease: a meta-analysis of double-blind,
placebo-controlled trials. Clin Gastroenterol Hepatol 2004;2:379-388.
23 Mantzaris GJ, Sfakianakis M, Archavlis E, et al. A prospective randomized observer-blind 2-year trial of azathioprine
monotherapy versus azathioprine and olsalazine for the maintenance of remission of steroid-dependent ulcerative
colitis. Am J Gastroenterol 2004;99:1122-1128.
24 Cuffari C, Dassopoulos T, Turnbough L, et al. Thiopurin methyltransferase activity influences clinical response to
azathiopurine in inflammatory bowel disease. Clin Gastroenterol Hepatol 2004;2:410-417.
25 Hanauer SB, Korelitz BI, Rutgeerts P, et al. Postoperative maintenance of Crohn’s disease remission with 6-
mercaptopurine, mesalamine, and placebo: a 2-year trial. Gastroenterology 2004;127:723-729.
26 Moskowitz DN, Bodian C, Chapman ML, Marion JF, et al. The effect on the fetus of medications used to treat
pregnant inflammatory bowel disease patients, Am J Gastroenterol 2004;99:656-660.
27 Van Staa TP, Travis S, Leufkens HGM, Logan RF. 5-aminosalicylic acids and the risk of renal disease. A large british
epidemiologic study. Gastroenterology 2004;126:1733-1739.
28 Sands BE, Anderson FH, Bernsteint CN, et al. Infliximab maintenance therapy for fistulizing Crohn’s disease. N Engl
J Med 2004;350:876-885.
29 Sandborn, WJ, Feagan BG, Radford-Smith G, et al. CDP-571, a humanised monoclonal antobody to tumour necrosis
factor α, for moderate to severe Crohn’s disease: a randomised, dfouble blind, placebo controlled trial. Gut
2004;53:1485-1493.
30 Sandborn WJ, Hanauer SB, Loftus EV, et al. An open-label study of the human anti-TNF monoclonal antobody
adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn’s disease. Am J Gastroenterol
2004;99:1984-1989.
31 Mannon PJ, Fuss IJ, Mayer L, et al. Anti-interleukin-12 antibody for active Crohn’s disease. N Engl J Med
2004;351:2069-2079.
32 Parsi M, Lashner BA, Achkar JP, et al. Type of fistula determinates pesponse to infliximab in patients with fistulous
Crohn’s disease. Am J Gastroenterol 2004;99:445-449.
33 Sands BE, Blank MA, Patel K et al. Long-term treatmwent of rectovaginal fistulas in Crohn’s disease: response to
infliximab in the ACCENT II study. Clin Gastroenterol Hepatol 2004;2:912-920.
34 Rasul I, Wilson SR, MacRaeH, Greenberg GR. Clinical and radiological responses after infliximab treatment for
perianal fistulizing Crohn’s disease. Am J. Gastroenterol 2004;99:82-88.
35 *Colombel JF, Loftus EV, Tremaine WJ, et al. Early postoperative complications are not increased in patients with
Crohn’s disease treated preoperatively with infliximab or immunosuppressive therapy. Am J Gastroenterol 2004;99:878-
883.
36 Ljung T, Karlén P, Schmidt PM, et al. Infliximab in inflammatory bowel disease: clinical outcome in a population
based cohort from Stockholm county. Gut 2004;53:849-853.
37 Burgmann T, Rawsthorne P, Bernstein CN. Predictors of alternative and complemenary medicine use in inflammatory
bowel disease: do measures of coventional health care utilization relate to use. Am J Gastroenterol 2004;99:889-893.
38 Mimura T, Rizzello F, Hellwig U, et al. Once high dose probiotic therapy (VSL#3) for maintaining remission in
recurrent or refractory pouchitis. Gut 2004;53:108-114.
39 Yang YX, Henessy S, Lewis JD. Insulin therapy and colorectal cancer risk among type 2 diabetes mellitus patients.
Gastoenterology 2004;127:1044-1050.
40 Hendricks YMC, Wagner A, Morreau H, et al. Cancer risk in hereditary nonpolyposis colorectal cancer due to MSH6
mutations: impact on counseling and surveillance.
41 Chlebowski RT, Wactawski-Wende J, Ritenbaugh C, et al. Estrogen plus progestin and colorectal cancer in
postmenopausal women. N Engl J Med 2004;350:991-1004.
42 Cho E, Smith-Warner SA, Ritz J, et al. Alcohol intake and colorectal cancer: a pooled analysis of 8 cohort studies.
Ann Int Med 2004;140:603-603.
43 Anderson JC, Attam R, Alpern Z, et al. Prevalence of colorectal neoplasia in smokers. Am J Gastroenterol
2003;98:2777-2783.
44 Larsson SC, Bergkvist L, Wolk A. Magnesium intake in relation to risk of colorectal cancer in women. JAMA
2005;293:86-69.
45 Chao A, Thun MJ, Connell CJ,. et al. Meat consumption and risk of colorectal cancer. JAMA 2005;293:171-182.
46 Erlinger TP, Platz EA, Rifai N, Helzlsouner KJ. C-reactive protein and the risk of colorectal cancer. JAMA
2004;291;585-590.
47 Chan AT, Giovanucci EL, Schernhammer ES, et al. A prospective study of aspirin use and the risk for colorectal
adenoma. Ann Int Med 2004;140:157-166.
48 Imperiale TF, Ransohoff DF, Itzkowitz SH, et al. Fecal DNA versus fecal occult blood cor colorectal-cancer screening
in an average-risk population. N Engl J Med 2004;351:2704-2714.
49 Brand RE, Ross mE, Shuber AP. Reproducibility of a multitarget stool-based DNA assay for colorectal cancer
detection. Am J Gastroenterol 2004;99:1338-1341.
50 Müller HM, Oberwalder M, Fiegl H, et al. Methylation changes in faecal DNA: a marker for colorectal cancer
screening. Lancet 2004;363:1283-1285.
51 Farraye FA, Wong M, Hurwitz S, et al. Barriers to endoscopic colorectal cancer screening: are women different from
men? Am J Gastroenterol 2004;99:341-349.
52 Sheikh RA, Kapre S, Calof OM, et al. Screening preferences for colorectal ancer: a patient demografic study. Southern
Med Ass 2004;97:224-230.
53 Murray CDR, Flynn J, Ratcliffe L, et al. Effect of acute physical and psychological stress on gbut autonom
innervation in irritable bowel syndrome. Gatroenterology 2004;127:1695-1703.
54 Gwee KA, Wee SW, Wong ML et al. The prealence, symptom characteristics, and impact of irritable bowel syndrome
in an Asian urban community. Am J Gastroenterol 2004;99:924-931.
55 Howell S, Talley NJ, Quine S, Poulton R. The irritable bowel syndrome has origins in childhood socioeconomic
environment. Am J Gastroenterol 2005;99:1572-1578.
56 Okhuysen PC, Jiang ZD, Carlin L, et al. Post-Diarrhea chronic intestinal symptoms in North American trevelers to
Mexico. Am J Gastroenterol 2005;99:1774-1778.
57 Mearin F, Baró E, Roset M, et al. Clinical patterns over time in irritable bowel syndrome: symptom instability and
severity variability. Am J Gastroenterol 2004;99:113-121.
58 Miller V, Hopkins L, Whorwell PJ. Suicidal ideation inpatients with irritable bowel syndroma. Clin Gastroenterol
Hepatol 2004;2:1064-1068.
59 Longstreth G, Yao JF. Irritable bowel syndrome and surgery: a multivariable analysis. Gastroenterology
2004;126:1665-1673.
60 Lembo AJ, Olden KW, Ameen WZ, et al. Effect of alosetron on bowel urgency and global symptoms in women with
severe, diarrhea-predominant irritable bowel syndrome: analisis of two controlled trials. Clin Gastroenterol Hepatol
20042:675-682
61 Johal SS, Hammond J, Solomon K, et al. Clostridium difficile associated diarrhoea in hospitalised patients: onset in
the community and hospital and role of flexible sigmoidoscopy. Gut 2004;53:673-677.
62 Cappel MS. Colonic toxicity of administered drugs and chemicals. Am J Gastroenterol 2004;99:1175-1190.
63 Higgins PDR, Juhanson JF. Epidemiology of constipation in North America: a systemic review. Am J Gastroenterol
2004;99:750-759.
64 Johanson JF, Wald A, Tougas G, et al. Effect of tegaserod in chronic constipation: a randomized double-blind,
controlled trial.Clin Gastroenterol Hepatol 2004;2:796-805
65 West J, Logan RFA, Smith CJ, et al. Malignancy and mortality in people with coeliac disease: population based cohort
study. BMJ 2004;329:716-718.
66 Olesen M, Eriksson S, Bohr J, et al. Lymphocytic colitis: a retrospective clinical study of 199 Swedish patients. Gut
2004;53:536-541.
